Giant nonfunctional ectopic adrenocortical carcinoma on the anterior abdominal wall: A case report

Dong-Kai Zhou, Zheng-Hao Liu, Bing-Qiang Gao, Wei-Lin Wang

Abstract

BACKGROUND
Adrenocortical cancer (ACC) is an infrequent and often aggressive malignancy with a very poor prognosis. It can be classified as functional or nonfunctional. Nonfunctional ACC is hampered by the absence of specific signs or symptoms; only abdominal pain with or without incidental adrenal occupation is typically present.

CASE SUMMARY
We report a rare case of a patient with a 30 cm × 15 cm × 8 cm ectopic ACC on the anterior abdominal wall without organ adhesion. A 77-year-old male was admitted to our hospital because of a huge abdominal mass, which, by ultrasonography, had an unclear border with the liver. Computed tomography showed that the mass was not associated with any organ but was adherent to the anterior abdominal wall. The patient underwent tumor resection, and a postoperative pathology examination showed a neuroendocrine tumor, which was diagnosed as ACC. The patient was disease-free at the 9-mo follow up.

CONCLUSION
The anterior abdominal wall is a rare site of ACC growth.

Key words: Adrenocortical carcinoma; Nonfunctional; Ectopic; Abdominal wall; Case
INTRODUCTION

Adrenocortical cancer (ACC) is an infrequent and often aggressive malignancy with a very poor prognosis. According to the Surveillance, Epidemiology and End Results database, ACC has an annual incidence of 0.7-2 per million population[1] and a bimodal age distribution with peaks before 5 years of age and at 40-60 years of age[2].

ACC can be classified as functional or nonfunctional. The early diagnosis and treatment of nonfunctional ACC is hampered by the absence of specific signs or symptoms; only abdominal pain with or without incidental adrenal occupation is typically present. Based on its cost-effectiveness, the American Association of Clinical Endocrinologists guidelines recommend surgery for nonfunctional ACC lesions ≥ 4 cm in diameter[3]. Here, we report the case of a patient with ACC on the abdominal wall. The patient underwent tumor resection and was disease-free at the 9-mo follow up.

CASE PRESENTATION

Chief complaints
A 77-year-old male (body mass index, 24.5 kg/m²), who 9 mo previously had been admitted to our hepatological surgery department, presented with an enormous exogenous liver occupation that had been detected by ultrasonography in a community hospital 2 d prior. He denied having abdominal pain, nausea, anorexia, or changes in bowel habit.

History of present illness
The patient had no clinical symptoms associated with steroid excess, except for hypertension. He was admitted to our department for diagnosis.

History of past illness
The patient had suffered from hypertension for 40 years but did not have diabetes or cardiovascular disease.

Personal and family history
His medical history and family history were unremarkable.

Physical examination
The results of a physical examination were unremarkable, except for a palpable hard mass and slight tenderness in the hepatic region.

Laboratory examinations
The results of laboratory tests were as follows: CA199, 112.0 U/mL (reference < 37.0 U/mL); alpha fetoprotein, 1.4 ng/mL (reference < 20.0 ng/mL); alanine transaminase, 89 U/L (reference < 35.0 U/L); aspartate transaminase, 49 U/L (reference < 40 U/L); and serum potassium, 4.40 mmol/L (reference 3.50-5.20 mmol/L). The results of the endocrine work-up were negative.
**Imaging examinations**

Ultrasonography revealed an enormous space-occupying lesion in the right upper abdomen, in which Color Doppler flow imaging showed a small amount of blood flow (Figure 1A). A left-hepatic origin was considered, but contrast-enhanced computed tomography (CT) showed an irregular fat-containing mass in the right upper abdominal cavity of uneven density with an obscure boundary (Figure 1B). The tumor exhibited heterogeneous enhancement in the arterial phase (Figure 1C) and delayed enhancement in the venous phase (Figure 1D).

**TREATMENT**

A laparotomy was performed. During surgery, a 30 cm × 15 cm × 8 cm tumor was found above the hepatic curvature of the colon in front of the right posterior peritoneum (Figure 2). The liver, pancreas, stomach, colon, and adrenal gland were not infringed, and there was no lymph-node metastasis. The tumor had invaded the local right-abdominal musculature.

**FINAL DIAGNOSIS**

A postoperative pathology examination indicated that the tumor was hypo-differentiated carcinoma with neuroendocrinalization and so was considered to be ACC. A histopathology examination showed a Weiss score of 6, as cells were distributed in sheets and wide bands, and extensive necrosis was present. The cytoplasm was eosinophilic, the karyotype was irregular, and giant neoplastic cells were present (Figure 3A). The Ki-67 labeling index was > 80% (Figure 3B), and the tumor cells were positive for melan A, vimentin, synaptophysin (Figure 3C-E), CK20, insulin-like growth factor-2 (IGF-2), and EMA; and negative for CK (pan), inhibin a, CgA, and S-100.

**OUTCOME AND FOLLOW-UP**

The patient underwent regular follow ups involving a physical examination, laboratory testing, and X-ray and CT imaging. He was disease-free at the 9-mo follow up.

**DISCUSSION**

ACC is a rare malignancy, accounting for about 0.05%-0.2% of all malignant tumors, and has an annual incidence of 1–2 per million[4]. Ectopic adrenal tissue is commonly found in infants and children, but it is less common in adults[5]. ACC is the second most aggressive malignant endocrine tumor after anaplastic thyroid cancer[6]. Aberrant adrenal tissue can be found anywhere, but typically in the testes, ovaries, spermatic cord, and kidneys[6]. The most common site is retroperitoneal fat near the adrenal gland[7,8]; the bilateral lungs[9], liver[9], spleen[9], pancreas[9], colon[9], duodenum[9], and ovary[9] are less common. This is, to our knowledge, the first report of ACC on the anterior abdominal wall in the English-language literature.

The clinical symptoms of primary ACC are dependent on the functional state and volume of the tumor. Around half of patients with ACC are asymptomatic or have symptoms caused by mechanical effects of tumor growth[2], such as abdominal pain, nausea, poor appetite, and back pain[1]. The other half of patients with ACC have symptoms related to elevated levels of steroid hormones—Cushing syndrome, Conn syndrome, and feminization. ACC lesions are typically large as they grow rapidly; most are 10-13 cm in diameter, 9%-14% are < 6 cm, and 3% are < 4 cm[10]. Generally, nonfunctional ACC lesions are small; large nonfunctional ACC lesions are very rare[12].

The pathogenesis of ACC is unclear but is likely to involve IGF-2, tumor protein 53, and β-catenin. ACC can be diagnosed with 100% specificity and 96% sensitivity based on the levels of IGF-2 and Ki-67[13].

Imaging (magnetic resonance imaging or CT) is crucial for identifying adrenal involvement in ACC. In general, ACC is a non-homogeneous tumor with hemorrhage or necrosis and an irregular margin. Nuclear aberrations—comprising a high mitotic count, high nuclear grade, and bizarre mitotic figures—are characteristic histological findings of ACC[13].
Complete surgical resection is the only potentially curative therapy for ACC; and it is equally important to choose surgical indications according to the latest guidelines for the surgeon\(^{[14]}\). Indeed, complete resection is the most accurate predictor of the outcome. Paton \( et \ al\)^{[11]} reported that patients who have complete resection have a higher 5-year survival rate than those who have incomplete resection. In the retrospective study of Terzolo \( et \ al\)^{[15]}, use of mitotane as adjunct therapy reduced the rates of recurrence and mortality, as did etoposide, doxorubicin and cisplatin plus mitotane, streptozotocin plus mitotane, and gemcitabine plus capecitabine\(^{[1,16]}\).

The 5-year overall survival rate of patients with ACC is 37%-47\(^{[1]}\). For advanced ACC, \( i.e. \), stage III tumor), the mENS\(+\)T TNM classification - which comprises the “GRAF” components: grade (G), resection status (R), age (A), and functioning symptoms at diagnosis (defined as tumor or hormone-related symptoms) (F) - is recommended\(^{[17]}\). Rupture of the tumor capsule, metastasis, and a high Ki67 index are associated with reduced disease-free and overall survival.

**CONCLUSION**

ACC is rare and has a poor prognosis. The 5-year overall survival rate of patients with ACC is 37%-47\%, and resection is the optimum treatment modality. We describe a case of a patient with ectopic adrenocortical carcinoma on the anterior abdominal wall and our patient was disease-free at 9 mo after resection of the tumor.
Figure 2  The 30 cm × 15 cm × 8 cm heterogeneous tumor with necrosis (A, B). Arrows invaded abdominal wall tissue.

Figure 3  Histological staining. A: Histological staining showing significant nuclear atypia, necrosis, and pleomorphism of the tumor cells (magnification, 200×); B: The Ki-67 labeling index was > 80% (IHC staining; magnification, 50×); C-D: Positive IHC staining for (C) melan-A, (D) vimentin and (E) synaptophysin (magnification, 200×).

REFERENCES
Zhou DK et al. Ectopic ACC on the anterior abdominal wall

1. Fassnacht M, Libé R, Kroiss M, Allolio B. Adrenocortical carcinoma: a clinician's update. Nat Rev Endocrinol 2011; 7: 323-335 [PMID: 21386792 DOI: 10.1038/nrendo.2010.235]

2. Lam AK. Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours. Endocr Pathol 2017; 28: 213-227 [PMID: 28477311 DOI: 10.1007/s12022-017-9484-5]

3. Wang TS, Cheung K, Roman SA, Sosa JA. A cost-effectiveness analysis of adrenalectomy for nonfunctional adrenal incidentalomas: is there a size threshold for resection? Surgery 2012; 152: 1125-1132 [PMID: 22989891 DOI: 10.1016/j.surg.2012.08.011]

4. Libé R. Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment. Front Cell Dev Biol 2015; 3: 45 [PMID: 26191527 DOI: 10.3389/fcell.2015.00045]

5. Ayala AR, Basaria S, Udelman R, Westra WH, Wand GS. Corticotropin-independent Cushings syndrome caused by an ectopic adrenal adenoma. J Clin Endocrinol Metab 2000; 85: 2903-2906 [PMID: 10949001 DOI: 10.1210/jcem.85.8.6749]

6. Chentli F, Terki N, Azzaoui S. Ectopic adrenocortical carcinoma located in the ovary. Eur J Endocrinol 2016; 175: K17-K23 [PMID: 27523914 DOI: 10.1530/EJE-16-0224]

7. Park WY, Seo HI, Choi KU, Kim A, Kim YK, Lee SJ, Lee CH, Huh GY, Park DY. Three cases of adrenocortical tumors mistaken for hepatocellular carcinomas/diagnostic pitfalls and differential diagnosis. Ann Diagn Pathol 2017; 31: 9-13 [PMID: 29146602 DOI: 10.1016/j.anndiagpath.2017.05.016]

8. Marincola Smith P, Kierman CM, Tran TB, Postlewalt LM, Maithel SK, Prescott I, Pawlik T, Wang TS, Glenn J, Hataras I, Shenoy R, Phay J, Shirley LA, Fields RC, Jin L, Weber S, Saleem A, Sicklick J, Gad S, Yopp A, Mansour J, Duh QY, Seiser N, Votanopoulos K, Levine EA, Poultsides G, Solórzano CC. Role of Additional Organ Resection in Adrenocortical Carcinoma: Analysis of 167 Patients from the U.S. Adrenocortical Carcinoma Database. Ann Surg Oncol 2018; 25: 2308-2315 [PMID: 29868977 DOI: 10.1254/si0438-16:646664]

9. Arora S, Damle NA, Aggarwal S, Passah A, Behera A, Arora G, Bal C, Tripathi M. Prostate-Specific Membrane Antigen Expression in Adrenocortical Carcinoma on 68Ga-Prostate-Specific Membrane Antigen PET/CT. Clin Nucl Med 2018; 43: 449-451 [PMID: 29578871 DOI: 10.1097/RLU.0000000000002064]

10. Sturgeon C, Shen WT, Clark OH, Duh QY, Kebebew E. Risk assessment in 457 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy? J Am Coll Surg 2006; 202: 423-430 [PMID: 16500246 DOI: 10.1016/j.jamcollsurg.2005.11.005]

11. Paton BL, Novitsky YW, Zery M, Harrell AG, Norton JJ, Asbun HJ, Kercher KW, Heniford BT. Outcomes of adrenocortical carcinoma in the United States. Surgery 2006; 140: 914-20, discussion 919-20 [PMID: 17188138 DOI: 10.1016/j.surg.2006.07.035]

12. Tauchmanova L, Colao A, Marzano LA, Sbariano, Camera L, Rossi A, Palmiere G, Marzano E, Salvatore M, Pettinato G, Lombardi G, Rossi R. Andrenocortical carcinomas: twelve-year prospective experience. World J Surg 2004; 28: 896-903 [PMID: 15593464 DOI: 10.1007/s00268-004-7296-5]

13. Lerrario AM, Moraits A, Hammer GD. Genetics and epigenetics of adrenocortical tumors. Mol Cell Endocrinol 2014; 386: 67-84 [PMID: 24220673 DOI: 10.1016/j.mce.2013.10.028]

14. Isik A, Firat D, Yilmaz I, Peker K, Idiz O, Yilmaz B, Demiryilmaz I, Celebi F. A survey of current approaches to thyroid nodules and thyroid operations. Int J Surg 2018; 54: 100-104 [PMID: 29709542 DOI: 10.1016/j.ijsu.2018.04.037]

15. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Canton PA, Rossetto R, Buci L, Sperone, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Hahner S, Koschier AC, Arvat E, Ambrosi B, Loi P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 2007; 356: 2372-2380 [PMID: 17554118 DOI: 10.1056/NEJMoa063360]

16. Henning JEK, Deutschbein T, Altiere B, Steinhauer S, Kircher S, Sbiera S, Wild V, Schültert W, Kroiss M, Perotti P, Rosenwald A, Berruti A, Fassnacht M, Ronchi CL. Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors. J Clin Endocrinol Metab 2017; 102: 4323-4332 [PMID: 29092062 DOI: 10.1210/jc.2017-01624]

17. Libé R, Borget I, Ronchi CL, Zaggia B, Kroiss M, Kerkhofs T, Bertherat J, Volante M, Quinkler M, Chentli F, Terki N, Azzaoui S. Ectopic adrenocortical carcinoma (ACC): an European Network for the Study of Adrenal Tumour (ENSAT) study. Ann Oncol 2015; 26: 2119-2125 [PMID: 26392430 DOI: 10.1093/annonc/mdv329]
